India, May 16 -- Ipsen SA (IPN.PA,IPSEY) presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen's first-in-class recombinant neuroinhibitor, RNITM.
In the trial, at Week 4, 66% of patients treated with corabotase (50ng) showed a statistically significant =2-grade improvement (composite response) vs 0% with placebo. 54.3% of patients treated with Dysport showed a >2-grade improvement (composite response) at Week 4. At Week 24, 60.8% of patients treated with corabotase (50ng) experienced clinically significant sustained duration of effect vs placebo (0.2%) and vs Dysport (36.7%), defined as an investigator-assessed score of "none" or "mild" of line...